Overview

Treatment With Pazopanib for Neoadjuvant Breast Cancer

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the treatment of a doxorubicin in combination with cyclophosphamide followed by a combination of pazopanib in combination with paclitaxel prior to surgery results in a pathological complete response in females with breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Collaborator:
NSABP Foundation Inc
Treatments:
Albumin-Bound Paclitaxel
Cyclophosphamide
Doxorubicin
Liposomal doxorubicin
Paclitaxel